AlzeCure’s Alzheimer’s project receives approval to start next clinical phase I study with ACD856
Stockholm, Sweden, August 30, 2021. AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company has received approval from the regulatory authorities in Sweden to begin the next clinical phase I study (multiple ascending dose, MAD) with the candidate drug ACD856 focused on Alzheimer's disease.The MAD Phase I study is AlzeCure's third clinical study with ACD856, the lead candidate drug within the